Phages and immunomodulation

Future Microbiology

Volumn 12, Issue 10, 2017, Pages 905-914

  Górski, Andrzej ^a,b   Dąbrowska, Krystyna ^a   Miȩdzybrodzki, Ryszard ^a,b   Weber Dąbrowska, Beata ^a   Łusiak Szelachowska, Marzanna ^a   Jończyk Matysiak, Ewa ^a   Borysowski, Jan ^b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

cytokines; gut; immunity; lymphocytes; microbiome; phages; platelets

Indexed keywords

ANTINEOPLASTIC AGENT;

BACTERIOPHAGE; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGY; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTE; MICROFLORA; PATHOGENICITY; PHAGE THERAPY; PHAGOCYTE; PROCEDURES; THROMBOCYTE; VIROLOGY; VIRUS; VIRUS INFECTION;

ANTICARCINOGENIC AGENTS; BACTERIOPHAGES; BLOOD PLATELETS; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM; IMMUNITY; IMMUNOMODULATION; INFLAMMATION; LYMPHOCYTES; MICROBIOTA; PHAGE THERAPY; PHAGOCYTES; VIRUS DISEASES; VIRUSES;

EID: 85026906563     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2017-0049     Document Type: Review

References (74)

1. Relman D. The human microbiome and the future practice of medicine. JAMA 314(11), 1127-1128 (2015).
2. Marino E. The gut microbiota and immune-regulation: The fate of health and disease. Clin. Transl. Immunol. 5(11), e107 (2016).
3. Burcelin R. Gut microbiota and immune crosstalk in metabolic disease. Mol. Metab. 5(9), 771-781 (2016).
4. Brodin P, Davis MM. Human immune system variation. Nat. Rev. Immunol. 17(1), 21-29 (2017).
5. Garrett WS. Gut microbiota in 2016: A banner year for gut microbiota research. Nat. Rev. Gastroenterol. Hepatol. 14(2), 78-80 (2017).
6. Hutch Magazine. www.fhcrc.org
7. Braciale TJ, Hahn YS. Immunity to viruses. Immunol. Rev. 255(1), 5-12 (2013).
8. Alcami A, Ghazal P, Yewdell JW. Viruses in control of the immune system. Workshop on molecular mechanisms of immune modulation: lessons from viruses. EMBO Rep. 3(10), 927-932 (2002).
9. Lederberg J. Smaller fleasad infinitum: Therapeutic bacteriophage redux. Proc. Natl Acad. Sci. USA 93(8), 3167-3168 (1996).
10. Abeles SR, Pride DT. Molecular bases and role of viruses in the human microbiome. J. Mol. Biol. 426(23), 3892-3906 (2014).
11. Mills S, Shanahan F, Stanton C, Hill C, Coffey A, Ross RP. Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes 4(1), 4-16 (2013).
12. Górski A, Weber-Dąbrowska B. The potential role of endogenous bacteriophages in controlling invading pathogens. Cell. Mol. Life Sci. 62(5), 511-519 (2005).
13. Górski A, WaZna E, Weber-Dąbrowska B, Dąbrowska K, Świtała-Jeleń K, Miȩdzybrodzki R. Bacteriophage translocation. FEMS Immunol. Med. Microbiol. 46(3), 313-319 (2006).
14. Górski A, Dąbrowska K, Świtała-Jeleń K et al. New insights into the possible role of bacteriophages in host defense and disease. Med. Immunol. 2(1), 2 (2003).
15. Barr JJ, Auro R, Furlan M. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc. Natl Acad. Sci. USA 110(26), 10771-10776 (2013).
16. Górski A, Miȩdzybrodzki R, Borysowski J et al. Phage as a modulator of immune responses: practical implications for phage therapy. Adv. Virus Res. 83, 41-71 (2012).
17. Kim KP, Cha JD, Jang EH et al. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb. Biotechnol. 1(3), 247-257 (2008).
18. Górski A, Kniotek M, Perkowska-Ptasińska A et al. Bacteriophages and transplantation tolerance. Transplant. Proc. 38(1), 331-333 (2006).
19. Thammavongsa V, Kim HK, Missiakas D, Schneewind O. Staphylococcal manipulation of host immune responses. Nat. Rev. Microbiol. 13(9), 529-543 (2015).
20. Dąbrowska K, Miernikiewicz P, Piotrowicz A et al. Immunogenicity studies of proteins forming the T4 phage head surface. J. Virol. 88(21), 12551-12557 (2014).
21. Majewska J, Beta W, Lecion D et al. Oral application of T4 phage induces weak antibody production in the gut and in the blood. Viruses 7(8), 4783-4799 (2015).
22. Bruttin A, Brössow H. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob. Agents Chemother. 49(7), 2874-2878 (2005).
23. Łusiak-Szelachowska M, Zaczek M, Weber-Dąbrowska B et al. Antiphage activity of sera during phage therapy in relations to its outcome. Future Microbiol. 12(2), 109-117 (2017).
24. Zaczek M, Łusiak-Szelachowska M, Jończyk-Matysiak E et al. Antibody production in response to staphylococcal MS-1 phage cocktail in patients undergoing phage therapy. Front. Microbiol. 7, 1681 (2016).
25. Górski A, Dąbrowska K, Hodyra-Stefaniak K, Borysowski J, Miȩdzybrodzki R, Weber-Dąbrowska B. Phages targeting infected tissues: novel approach to phage therapy. Future Microbiol. 10(2), 199-204 (2015).
26. Górski A, Miȩdzybrodzki R, Weber-Dąbrowska B. Phage therapy: combating infections with potential for evolving from merely a treatment for complications to targeting diseases. Front. Microbiol. 7, 1515 (2016).
27. Jain L, Rawat M, Ramakrishnan S, Kumar B. Active immunization with Brucella abortus S19 phage lysate elicits serum IgG that protects guinea pigs against virulent B. abortus and protects mice by passive immunization. Biologicals 45, 27-32 (2017).
28. Borysowski J, Wierzbicki P, Kłosowska D, Korczak-Kowalska G, Weber-Dąbrowska B, Górski A. The effects of T4 and A3/R phage preparations on whole-blood monocyte and neutrophil respiratory burst. Viral Immunol. 23(5), 541-544 (2010).
29. Miȩdzybrodzki R, Świtała-Jeleń K, Fortuna W et al. Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. Virus Res. 131(2), 233-242 (2008).
30. Przerwa A, Zimecki M, Świtała-Jeleń K et al. Effects of bacteriophages on free radical production and phagocytic functions. Med. Microbiol. Immunol. 195(3), 143-150 (2006).
31. Jończyk-Matysiak E, Łusiak-Szelachowska M, Kłak M et al. The effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes. J. Immunol. Res. 2015, 482863 (2015).
32. Bocian K, Borysowski J, Zarzycki M et al. LPS-Activated monocytes are unresponsive to T4 phage and T4-generated Escherichia coli lysate. Front. Microbiol. 7, 1356 (2016).
33. Bocian K, Borysowski J, Zarzycki M et al. The effects of T4 and A3/R bacteriophages on differentiation of human myeloid dendritic cells. Front. Microbiol. 7, 1267 (2016).
34. Miernikiewicz P, Dąbrowska K, Piotrowicz A et al. T4 phage and its head surface proteins do not stimulate inflammatory mediator production. PLoS ONE 8(8), e71036 (2013).
35. Pajtasz-Piasecka E, Rossowska J, Duś D, Weber-Dąbrowska B, Zabłocka A, Górski A. Bacteriophages support anti-Tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma. Immunol. Lett. 116(1), 24-32 (2008).
36. An TW, Kim SJ, Lee YD, Park JH, Chang HI. The immune-enhancing effect of the Cronobacter sakazakii ES2 phage results in the activation of nuclear factor kB and dendritic cell maturation via the activation of IL-12p40 in the mouse bone marrow. Immunol. Lett. 157(1-2), 1-8 (2014).
37. Borysowski J, Miȩdzybrodzki R, Wierzbicki P et al. A3R phage and Staphylococcus aureus lysate do not induce neutrophil degranulation. Viruses 9(2), 36 (2017).
38. Miernikiewicz P, Kłopot A, Soluch R et al. T4 phage tail adhesin gp12 counteracts LPS-induced inflammation in vivo. Front. Microbiol. 7, 1112 (2016).
39. Secor PR, Michaels LA, Smigiel KS et al. Filamentous bacteriophage produced by Pseudomonas aeruginosa alters the inflammatory response and promotes noninvasive infection in vivo. Infect. Immun. 85(1), pii:e00648-16 (2016) (Epub ahead of print).
40. Wang Z, Zheng P, Ji W et al. SLPW: A virulent bacteriophage targeting methicillin-resistant Staphylococcus aureus in vitro and in vivo. Front. Microbiol. 7, 934 (2016).
41. Pabary R, Singh C, Morales S et al. Antipseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung. Antimicrob. Agents Chemother. 60(2), 744-751 (2015).
42. Hong Y, Thimmapuram J, Zhang J et al. The impact of orally administered phages on host immune response and surrounding microbial communities. Bacteriophage 6(3), e1211066 (2016).
43. Stenina MA, Krivov LI, Voevodin DA, Savchuk VI, Kovalchuk LV, Yarygin VN. Cytokine profile of the blood in mice with normal and abnormal heart rhythm. Bull. Exp. Biol. Med. 152(6), 692-695 (2012).
44. Tothova L, Celec P, Babickova J et al. Phage therapy of Cronobacter-induced urinary tract infection in mice. Med. Sci. Monit. 17(7), BR173-BR178 (2011).
45. Hung CH, Kuo CF, Wang CH, Wu CM, Tsao N. Experimental phage therapy in treating Klebsiella pneumoniae mediated liver abscesses and bacteremia in mice. Antimicrob. Agents Chemother. 55(4), 1358-1365 (2011).
46. Park K, Cha KE, Myung H. Observation of inflammatory responses in mice orally fed with bacteriophage T7. J. Appl. Microbiol. 117(3), 627-633 (2014).
47. Cao F, Wang X, Wang L et al. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistant Klebsiella pneumoniae in mice. Biomed Res. Int. 2015, 752930 (2015).
48. Dufour N, Henry M, Ricard JD, Debarbieux L. Commentary: morphologically distinct Escherichia coli bacteriophages differ in their efficacy and ability to stimulate cytokine release in vitro. Front. Microbiol. 7, 1029 (2016).
49. Penner JC, Ferreira JA, Secor PR et al. Pf4 bacteriophage produced by Pseudomonas aeruginosa inhibits Aspergillus fumigatus metabolism via iron sequestration. Microbiology 162(9), 1583-1594 (2016).
50. Ekiz C, Agaoglu L, Karakas Z, Gurel N, Yalcin I. The effect of iron deficiency anemia on the function of the immune system. Hematol. J. 5(7), 579-583 (2005).
51. Bonaccorsi-Riani E, Danger R, Lozano JJ et al. Iron deficiency impairs intra-hepatic lymphocyte mediated immune response. PLoS ONE 10(8), e0136106 (2015).
52. Miȩdzybrodzki R, Borysowski J, Weber-Dąbrowska B et al. Clinical aspects of phage therapy. Adv. Virus Res. 83, 73-121 (2012).
53. Miȩdzybrodzki R, Fortuna W, Weber-Dąbrowska B, Górski A. A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin. Exp. Med. 9(4), 303-312 (2009).
54. Hashiguchi S, Yamaguchi Y, Takeuchi O, Akira S, Sugimura K. Immunological basis of M13 phage vaccine: regulation under MyD88 and TLR9 signaling. Biochem. Biophys. Res. Commun. 402(1), 19-22 (2010).
55. Eriksson F, Tsagozis P, Lundberg K et al. Tumor-specific bacteriophages induce tumor destruction through activation of tumor-Associated macrophages. J. Immunol. 182(5), 3105-3111 (2009).
56. Lepage P, Colombet J, Marteau P, Sime-Ngando T, Dore J, Leclerc M. Dysbiosis in inflammatory bowel disease: A role for bacteriophages? Gut 57(3), 424-425 (2008).
57. Riley PA. Bacteriophages in autoimmune disease and other inflammatory conditions. Med. Hypotheses 62(4), 493-498 (2004).
58. Iannacone M. Platelet-mediated modulation of adaptive immunity. Semin. Immunol. 28(6), 555-560 (2016).
59. Melki I, Tessandier N, Zufferey A, Boilard E. Platelet microvesicles in health and disease. Platelets doi:10.1080/09537104.2016.126592 4 (2017) (Epub ahead of print).
60. Koenen RR. The prowess of platelets in immunity and inflammation. Thromb. Haemost. 116(4), 605-612 (2016).
61. Świtała-Jeleń K. Studies on bacteriophage interactions with blood platelets and leukocytes. Doctoral thesis, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław (2005).
62. Rondina MT, Weyrich AS. Dengue virus pirates human platelets. Blood 126(3), 286-287 (2015).
63. Przybylski M, Borysowski J, Jakubowska-Zahorska R, Weber-Dąbrowska B, Górski A. T4 bacteriophage-mediated inhibition of adsorption and replication of human adenovirus in vitro. Future Microbiol. 10(4), 453-460 (2015).
64. Bloch H. Experimentelle untersuchungen uber beziehungen zwischen bakteriophagen und malignen tumoren. Archiv fur die Gesamte Virusforschung. 1(4), 481-496 (1940).
65. Dąbrowska K, Opolski A, Wietrzyk J et al. Antitumor activity of bacteriophages in murine experimental cancer models caused possibly by inhibition of beta3 integrin signaling pathway. Acta Virol. 48(4), 241-248 (2004).
66. Dąbrowska K, Opolski A, Wietrzyk J et al. Activity of bacteriophages in murine tumor models depends on the route of phage administration. Oncol. Res. 15(4), 183-187 (2005).
67. Dąbrowska K, Skardziński G, Jończyk E et al. The effect of bacteriophages T4 and HAP1 on in vitro melanoma migration. BMC Microbiol. 9, 13 (2009).
68. Dąbrowska K, Skaradziński G, Kurzȩpa A et al. The effects of staphylococcal bacteriophage lysates on cancer cells in vitro. Clin. Exp. Med. 10(1), 81-85 (2010).
69. Kurzȩpa-Skaradzińska A, Skaradziński G, Weber-Dąbrowska B et al. Influence of bacteriophage preparations on migration of HL-60 leukemia cells in vitro. Anticancer Res. 33(4), 1569-1574 (2013).
70. Dąbrowska K, Kaźmierczak Z, Majewska J et al. Bacteriophages displaying anticancer peptides in combined antibacterial and anticancer treatment. Future Microbiol. 9(7), 861-869 (2014).
71. Szczaurska-Nowak K, Dąbrowska K, Celka M et al. Antitumor effect of combined treatment of mice with cytostatic agents and bacteriophage T4. Anticancer Res. 29(6), 2361-2370 (2009).
72. Borysowski J, Górski A. Is phage therapy acceptable in the immunocompromised host? Int. J. Infect. Dis. 12(5), 466-471 (2008).
73. Borecky L. Use of bacteriophage nucleic acid inducers of interferon in man. Tex. Rep. Biol. Med. 35, 535-540 (1977).
74. Miȩdzybrodzki R, Fortuna W, Weber-Dąbrowska B, Górski A. Bacterial viruses against viruses pathogenic for man? Virus Res. 110(1-2), 1-8 (2005).